ClinicalTrials.gg
CompletedNCT01009242Updated Nov 15, 2024

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

A Phase 1/2 interventional study of CDP6038 and CDP6038 in Arthritis and Rheumatoid Arthritis, sponsored by UCB Pharma. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-15.

Primary conditionArthritis, RheumatoidRegistry: ArthritisReclassifiedWhy we changed it
Registry
Arthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Rheumatoid
Why
  1. The study's listed conditions name Arthritis, Rheumatoid, a narrower term within Arthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
9th of 10
40 · median 206
Started
2009
the only one that year
Phase 1/2
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
2 of 10
UCB Pharma

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is the only one that started in 2009, is the only one in phase 1/2, and was the 1st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be evaluated.

Read the detailed description

The secondary objectives of the study include determination of the absolute bioavailability of CDP6038 given via sc administration compared with iv infusion; assessment of the immunogenicity potential of single dose CDP6038 and assessment, on an exploratory basis, of other relevant systemic biomarkers and changes in clinical response.

03

Conditions studied

  • Arthritis
  • Rheumatoid Arthritis

Browse trials for

Keywords

  • CDP6038
04

In context

Arthritis, Rheumatoid Reclassified

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

This study's enrollment of 40 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RA > 6 months duration on stable Methotrexate
  • ≤9 swollen and ≤9 tender joints (28 joint count)
  • Minimum Screening CRP of 0.5mg/L

Exclusion criteria

Exclusion Criteria:

  • Participation in previous studies with defined agents and durations
  • Previous treatment with defined agents and durations
  • Presence of, or history of defined medical conditions including those particularly associated with deficiency in immune response
  • Pregnancy
  • Positive tests/signs of possible latent/active tuberculosis
  • Positive
  • Drug addiction or alcohol abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV

    Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.

    Biological: CDP6038 · Other: Placebo IV · Drug: Methotrexate

  • Experimental
    1 mg/kg CDP6038 SC and Placebo SC

    Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.

    Biological: CDP6038 · Other: Placebo SC · Drug: Methotrexate

  • Experimental
    Optimized CDP6038 SC

    Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.

    Drug: CDP 6038 SC · Drug: Methotrexate

Interventions

  • BiologicalCDP6038

    Single dose: 1 mg/kg CDP6038 IV

  • BiologicalCDP6038

    Single dose: 0.1mg/kg CDP6038 IV

  • BiologicalCDP6038

    Single dose: 1.0mg/kg CDP6038 SC

  • OtherPlacebo IV

    Single dose: Placebo IV

  • OtherPlacebo SC

    Single dose: Placebo SC

  • Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo

  • Individual stable doses of methotrexate.

07

What researchers measure

Primary outcomes

  1. PK/PD relationship between systemic CDP6038 exposure and CRP suppression.

    Time frame: For 12 weeks following single dose

  2. Evaluate the safety and tolerability of single doses of CDP6038 For 12 weeks following single dose

    Time frame: For 12 weeks following single dose

Secondary outcomes

  1. Absolute bioavailability of CDP6038 given by sc injection in comparison with iv infusion

    Time frame: For 12 weeks following single dose

  2. Assess the immunogenicity of single dose CDP6038

    Time frame: Multiple sampling from 0 to 12 weeks following single dose

  3. Assess, on an exploratory basis, changes in clinical response and other systemic biomarkers associated with RA

    Time frame: For 12 weeks following single dose

08

Study locations

6 sites
  • Duncansville, Pennsylvania, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Berlin, Germany
  • Cologne, Germany
  • Erlangen, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Sep 2010, 11 months.

Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2009
First posted
Nov 6, 2009
StartActual
Oct 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results delay requested
Oct 3, 2011
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01009242
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Nov 6, 2009
Start date
Oct 2009
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Nov 15, 2024

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion